| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Proceeds from issuance of common stock in connection with sale of stock-At Market Offerings | 2,017 | 2,017 |
| Net cash provided by financing activities | 51,909 | 52,194 |
| Increase in cash, cash equivalents and restricted cash | 48,492 | 66,272 |
| Cash and cash equivalents at beginning of period | 57,073 | - |
| Cash and cash equivalents at end of period | 105,565 | - |
Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc. (XLO)